Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.546    -0.034 (-5.86%)
Bid:
0.55
Ask:
0.60
Spread: 0.05 (9.091%)
Market Cap: £3.17m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

AGM Statement

24 Jun 2019 16:42

RNS Number : 2473D
Futura Medical PLC
24 June 2019
 

Results of Annual General Meeting

24 June 2019

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology currently focused on sexual health and pain, announces that at its Annual General Meeting, held earlier today, all resolutions were duly passed by the shareholders.

 

For further information please contact:

Futura Medical plc James Barder, Chief ExecutiveAngela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.comTel: +44 (0) 1483 685 670

Nominated Adviser and Sole Broker:LiberumBidhi Bhoma/ Euan Brown/ Kane CollingsTel: +44 (0) 203 100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 950 9144

 

Notes to editors:

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

 

The first European Phase 3 study for MED2005, referred to as "FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study of MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment of erectile dysfunction with an open label extension. FM57 is progressing on track, with headline data expected by the end of 2019.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGCKQDNPBKDFAB
Date   Source Headline
24th Jun 20207:00 amRNSTrading Statement
9th Jun 20202:06 pmRNSSecond Price Monitoring Extn
9th Jun 20202:00 pmRNSPrice Monitoring Extension
1st Jun 20207:00 amRNSBlock listing Interim Review
28th May 20204:40 pmRNSSecond Price Monitoring Extn
28th May 20204:35 pmRNSPrice Monitoring Extension
19th May 20204:40 pmRNSSecond Price Monitoring Extn
19th May 20204:35 pmRNSPrice Monitoring Extension
19th May 20202:00 pmRNSPrice Monitoring Extension
19th May 202011:05 amRNSSecond Price Monitoring Extn
19th May 202011:00 amRNSPrice Monitoring Extension
18th May 20207:00 amRNSNotice of AGM and Annual Report
6th May 202011:00 amRNSPrice Monitoring Extension
5th May 20204:36 pmRNSPrice Monitoring Extension
22nd Apr 20203:13 pmRNSDirector/PDMR Shareholding
21st Apr 20202:00 pmRNSPrice Monitoring Extension
20th Apr 20207:00 amRNSFutura files for Further Pre-Submission meeting
16th Apr 20202:00 pmRNSPrice Monitoring Extension
16th Apr 202011:05 amRNSSecond Price Monitoring Extn
16th Apr 202011:00 amRNSPrice Monitoring Extension
7th Apr 20204:41 pmRNSSecond Price Monitoring Extn
7th Apr 20204:36 pmRNSPrice Monitoring Extension
6th Apr 20204:41 pmRNSSecond Price Monitoring Extn
6th Apr 20204:36 pmRNSPrice Monitoring Extension
6th Apr 20207:00 amRNSFutura Confirms Receipt of US FDA Minutes
1st Apr 20207:00 amRNSFull Year Results for the year ended 31 Dec 2019
16th Mar 20207:00 amRNSNotice of Results
5th Mar 20207:00 amRNSFutura to Update on MED3000 at Investor Seminar
27th Feb 20209:37 amRNSHolding(s) in Company
17th Feb 202012:53 pmRNSHolding(s) in Company
13th Feb 20207:00 amRNSUpdate on positive EU regulatory discussions
30th Jan 20207:00 amRNSTotal Voting Rights
22nd Jan 20202:33 pmRNSRemuneration of NED and Total Voting Rights
21st Jan 20202:17 pmRNSHolding(s) in Company
21st Jan 20201:44 pmRNSHolding(s) in Company
17th Jan 202012:12 pmRNSGM Statement
7th Jan 202011:05 amRNSSecond Price Monitoring Extn
7th Jan 202011:00 amRNSPrice Monitoring Extension
27th Dec 20197:00 amRNSPosting of Circular and Notice of General Meeting
23rd Dec 20197:00 amRNSResult of Fundraising
20th Dec 20194:40 pmRNSSecond Price Monitoring Extn
20th Dec 20194:35 pmRNSPrice Monitoring Extension
20th Dec 20194:31 pmRNSPrimaryBid Offer
20th Dec 20194:30 pmRNSCorporate Update & Proposed Fundraising
17th Dec 20194:41 pmRNSSecond Price Monitoring Extn
17th Dec 20194:35 pmRNSPrice Monitoring Extension
17th Dec 201911:05 amRNSSecond Price Monitoring Extn
17th Dec 201911:00 amRNSPrice Monitoring Extension
16th Dec 20199:05 amRNSSecond Price Monitoring Extn
16th Dec 20199:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.